{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:49:09Z","timestamp":1776131349998,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10157-018-1679-7","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T10:26:35Z","timestamp":1544696795000},"page":"689-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effects of long-term treatment with low-GDP, pH-neutral solutions on peritoneal membranes in peritoneal dialysis patients"],"prefix":"10.1007","volume":"23","author":[{"given":"Mitsuhiro","family":"Tawada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieko","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kinashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuho","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9676-6961","authenticated-orcid":false,"given":"Yasuhiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"1679_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1681\/ASN.2009070694","volume":"21","author":"O Devuyst","year":"2010","unstructured":"Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol. 2010;21:1077\u201385.","journal-title":"J Am Soc Nephrol"},{"key":"1679_CR2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1681\/ASN.V132470","volume":"13","author":"JD Williams","year":"2002","unstructured":"Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13:470\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"1679_CR3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.2215\/CJN.03630807","volume":"3","author":"K Honda","year":"2008","unstructured":"Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T, et al. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol. 2008;3:720\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1679_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10047-013-0741-1","volume":"17","author":"H Nakamoto","year":"2014","unstructured":"Nakamoto H, Hamada C, Shimaoka T, Sekiguchi Y, Io H, Kaneko K, et al. Accumulation of advanced glycation end products and beta 2-microglobulin in fibrotic thickening of the peritoneum in long-term peritoneal dialysis patients. J Artif Organs. 2014;17:60\u20138.","journal-title":"J Artif Organs"},{"key":"1679_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/ki.2013.190","volume":"84","author":"Y Cho","year":"2013","unstructured":"Cho Y, Johnson DW, Badve SV, Craig JC, Strippoli GF, Wiggins KJ. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney Int. 2013;84:969\u201379.","journal-title":"Kidney Int"},{"key":"1679_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3747\/pdi.2015.00031","volume":"37","author":"K Farhat","year":"2017","unstructured":"Farhat K, Douma CE, Ferrantelli E, Ter Wee PM, Beelen RHJ, van Ittersum FJ. Effects of conversion to a bicarbonate\/lactate-buffered, neutral-pH, low-GDP PD regimen in prevalent PD: a 2-year randomized clinical trial. Perit Dial Int. 2017;37:273\u201382.","journal-title":"Perit Dial Int"},{"key":"1679_CR7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/089686080502500308","volume":"25","author":"HY Lee","year":"2005","unstructured":"Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int. 2005;25:248\u201355.","journal-title":"Perit Dial Int"},{"key":"1679_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3747\/pdi.2013.00074","volume":"34","author":"M Nakayama","year":"2014","unstructured":"Nakayama M, Miyazaki M, Honda K, Kasai K, Tomo T, Nakamoto H, et al. Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study. Perit Dial Int. 2014;34:766\u201374.","journal-title":"Perit Dial Int"},{"key":"1679_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1046\/j.1523-1755.2001.00497.x","volume":"59","author":"B Rippe","year":"2001","unstructured":"Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int. 2001;59:348\u201357.","journal-title":"Kidney Int"},{"key":"1679_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1046\/j.1523-1755.2001.0590041529.x","volume":"59","author":"S Jones","year":"2001","unstructured":"Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al. Bicarbonate\/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int. 2001;59:1529\u201338.","journal-title":"Kidney Int"},{"key":"1679_CR11","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1093\/ndt\/gfq702","volume":"26","author":"A Sawai","year":"2011","unstructured":"Sawai A, Ito Y, Mizuno M, Suzuki Y, Toda S, Ito I, et al. Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients. Nephrol Dial Transplant. 2011;26:2322\u201332.","journal-title":"Nephrol Dial Transplant"},{"key":"1679_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1681\/ASN.2012030226","volume":"24","author":"H Kinashi","year":"2013","unstructured":"Kinashi H, Ito Y, Mizuno M, Suzuki Y, Terabayashi T, Nagura F, et al. TGF-beta1 promotes lymphangiogenesis during peritoneal fibrosis. J Am Soc Nephrol. 2013;24:1627\u201342.","journal-title":"J Am Soc Nephrol"},{"key":"1679_CR13","doi-asserted-by":"publisher","first-page":"e0154644","DOI":"10.1371\/journal.pone.0154644","volume":"11","author":"M Tawada","year":"2016","unstructured":"Tawada M, Ito Y, Hamada C, Honda K, Mizuno M, Suzuki Y, et al. Vascular endothelial cell injury is an important factor in the development of encapsulating peritoneal sclerosis in long-term peritoneal dialysis patients. PLoS One. 2016;11:e0154644.","journal-title":"PLoS One"},{"key":"1679_CR14","doi-asserted-by":"publisher","first-page":"F167-80","DOI":"10.1152\/ajprenal.00052.2017","volume":"314","author":"T Kariya","year":"2018","unstructured":"Kariya T, Nishimura H, Mizuno M, Suzuki Y, Matsukawa Y, Sakata F, et al. TGF-beta1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis. Am J Physiol Renal Physiol. 2018;314:F167-80.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1679_CR15","doi-asserted-by":"publisher","first-page":"F721-33","DOI":"10.1152\/ajprenal.00368.2009","volume":"298","author":"M Mizutani","year":"2010","unstructured":"Mizutani M, Ito Y, Mizuno M, Nishimura H, Suzuki Y, Hattori R, et al. Connective tissue growth factor (CTGF\/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. Am J Physiol Renal Physiol. 2010;298:F721-33.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1679_CR16","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0272-6386(04)00953-9","volume":"44","author":"H Kawanishi","year":"2004","unstructured":"Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004;44:729\u201337.","journal-title":"Am J Kidney Dis"},{"key":"1679_CR17","first-page":"53","volume":"12","author":"R White","year":"1996","unstructured":"White R, Ram S. Peritoneal dialysis solution attenuates microvascular leukocyte adhesion induced by nitric oxide synthesis inhibition. Adv Perit Dial. 1996;12:53\u20136.","journal-title":"Adv Perit Dial"},{"key":"1679_CR18","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/ndt\/gfl054","volume":"21","author":"AM Sherif","year":"2006","unstructured":"Sherif AM, Nakayama M, Maruyama Y, Yoshida H, Yamamoto H, Yokoyama K, et al. Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD patients. Nephrol Dial Transplant. 2006;21:1675\u201381.","journal-title":"Nephrol Dial Transplant"},{"key":"1679_CR19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1681\/ASN.V1251046","volume":"12","author":"SJ Davies","year":"2001","unstructured":"Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001;12:1046\u201351.","journal-title":"J Am Soc Nephrol"},{"key":"1679_CR20","first-page":"123-7","volume":"29","author":"YL Kim","year":"2009","unstructured":"Kim YL. Update on mechanisms of ultrafiltration failure. Perit Dial Int. 2009;29:123-7.","journal-title":"Perit Dial Int"},{"key":"1679_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1744-9987.2007.00431.x","volume":"11","author":"CD Kim","year":"2007","unstructured":"Kim CD, Kwon HM, Park SH, Oh EJ, Kim MH, Choi SY, et al. Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascularization in a chronic rat model. Ther Apher Dial. 2007;11:56\u201364.","journal-title":"Ther Apher Dial"},{"key":"1679_CR22","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/j.1523-1755.2005.00237.x","volume":"67","author":"S Mortier","year":"2005","unstructured":"Mortier S, Faict D, Lameire NH, De Vriese AS. Benefits of switching from a conventional to a low-GDP bicarbonate\/lactate-buffered dialysis solution in a rat model. Kidney Int. 2005;67:1559\u201365.","journal-title":"Kidney Int"},{"key":"1679_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3747\/pdi.2011.00270","volume":"33","author":"K Kawanishi","year":"2013","unstructured":"Kawanishi K, Honda K, Tsukada M, Oda H, Nitta K. Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis. Perit Dial Int. 2013;33:242\u201351.","journal-title":"Perit Dial Int"},{"key":"1679_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10047-015-0822-4","volume":"18","author":"C Hamada","year":"2015","unstructured":"Hamada C, Honda K, Kawanishi K, Nakamoto H, Ito Y, Sakurada T, et al. Morphological characteristics in peritoneum in patients with neutral peritoneal dialysis solution. J Artif Organs. 2015;18:243\u201350.","journal-title":"J Artif Organs"},{"key":"1679_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3747\/pdi.2014.00038","volume":"36","author":"G Peso del","year":"2016","unstructured":"del Peso G, Jimenez-Heffernan JA, Selgas R, Remon C, Ossorio M, Fernandez-Perpen A, et al. Biocompatible dialysis solutions preserve peritoneal mesothelial cell and vessel wall integrity. a case\u2013control study on human biopsies. Perit Dial Int. 2016;36:129\u201334.","journal-title":"Perit Dial Int"},{"key":"1679_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/ndt\/13.1.154","volume":"13","author":"RJ Rigby","year":"1998","unstructured":"Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant. 1998;13:154\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1679_CR27","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1093\/ndt\/gfp008","volume":"24","author":"G Balasubramaniam","year":"2009","unstructured":"Balasubramaniam G, Brown EA, Davenport A, Cairns H, Cooper B, Fan SL, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009;24:3209\u201315.","journal-title":"Nephrol Dial Transplant"},{"key":"1679_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ki.2010.16","volume":"77","author":"DW Johnson","year":"2010","unstructured":"Johnson DW, Cho Y, Livingston BE, Hawley CM, McDonald SP, Brown FG, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int. 2010;77:904\u201312.","journal-title":"Kidney Int"},{"key":"1679_CR29","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/ndt\/gfp677","volume":"25","author":"AM Habib","year":"2010","unstructured":"Habib AM, Preston E, Davenport A. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial Transplant. 2010;25:1633\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"1679_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3747\/pdi.2010.00167","volume":"31","author":"MR Korte","year":"2011","unstructured":"Korte MR, Sampimon DE, Lingsma HF, Fieren MW, Looman CW, Zietse R, et al. Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int. 2011;31:269\u201378.","journal-title":"Perit Dial Int"},{"key":"1679_CR31","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10157-011-0471-8","volume":"15","author":"M Mizuno","year":"2011","unstructured":"Mizuno M, Ito Y, Tanaka A, Suzuki Y, Hiramatsu H, Watanabe M, et al. Peritonitis is still an important factor for withdrawal from peritoneal dialysis therapy in the Tokai area of Japan. Clin Exp Nephrol. 2011;15:727\u201337.","journal-title":"Clin Exp Nephrol"},{"key":"1679_CR32","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s10157-016-1249-9","volume":"20","author":"M Mizuno","year":"2016","unstructured":"Mizuno M, Ito Y, Suzuki Y, Sakata F, Saka Y, Hiramatsu T, et al. Recent analysis of status and outcomes of peritoneal dialysis in the Tokai area of Japan: the second report of the Tokai peritoneal dialysis registry. Clin Exp Nephrol. 2016;20:960\u201371.","journal-title":"Clin Exp Nephrol"},{"key":"1679_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3747\/pdi.2010.00234","volume":"32","author":"N Ayuzawa","year":"2012","unstructured":"Ayuzawa N, Ishibashi Y, Takazawa Y, Kume H, Fujita T. Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan. Perit Dial Int. 2012;32:159\u201367.","journal-title":"Perit Dial Int"},{"key":"1679_CR34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/labinvest.2015.87","volume":"95","author":"T Terabayashi","year":"2015","unstructured":"Terabayashi T, Ito Y, Mizuno M, Suzuki Y, Kinashi H, Sakata F, et al. Vascular endothelial growth factor receptor-3 is a novel target to improve net ultrafiltration in methylglyoxal-induced peritoneal injury. Lab Invest. 2015;95:1029\u201343.","journal-title":"Lab Invest"},{"key":"1679_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.kint.2016.03.040","volume":"90","author":"Q Zhou","year":"2016","unstructured":"Zhou Q, Bajo MA, Del Peso G, Yu X, Selgas R. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int. 2016;90:515\u201324.","journal-title":"Kidney Int"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1679-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1679-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1679-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T04:21:47Z","timestamp":1662610907000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1679-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1679-7","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"16 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y. Suzuki, F. Sakata, M. Mizuno and Y. Ito belong to the endowed department by Baxter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee for Human Research of the Faculty of Medicine at Nagoya University (Approval number 299) and Juntendo University (Approval number 26-010).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consents were obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}